{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T22:32:52Z","timestamp":1782340372392,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Vasculitis damage index (VDI) is a validated damage index for systemic vasculitis, and as Beh\u00e7et\u2019s disease is considered one of systemic vascular disease we aimed to study the relationship of the vasculitis damage index to clinical manifestations and comorbidity in patients with Beh\u00e7et\u2019s disease (BD) to determine if VDI could be used to assess damage in patients with BD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 109 patients with BD were recruited from the Rheumatology Department (outpatient and inpatient clinic), Cairo University Hospitals. All patients were subjected to full history taking, clinical examination, and routine laboratory investigations. Disease activity was assessed by the BD current activity form, and the VDI was calculated in all patients. The relationship of the VDI to the disease clinical manifestations was studied. Mann\u2013Whitney and Kruskal Wallis tests were used to estimate differences in quantitative variables. Spearman correlation test was used to test for correlation between quantitative variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the current study, the VDI ranged from 1 to 10, with a mean of 3.5\u2009\u00b1\u20091.8. It was significantly associated with total thrombosis (<jats:italic>P<\/jats:italic>\u2009=\u20090.022); total neurological manifestations (<jats:italic>P<\/jats:italic>\u2009=\u20090.000), especially stroke and cranial nerve affection; uveitis (<jats:italic>P<\/jats:italic>\u2009=\u20090.005); avascular necrosis (AVN) (<jats:italic>P<\/jats:italic>\u2009=\u20090.015); osteoporosis (<jats:italic>P<\/jats:italic>\u2009=\u20090.01); impaired vision (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001); cataract (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001); and diabetes (<jats:italic>P<\/jats:italic>\u2009=\u20090.012). Generally, immunosuppressive treatment was significantly associated with VDI (<jats:italic>P<\/jats:italic>\u2009=\u20090.039), especially cyclophosphamide (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), biological agent (<jats:italic>P<\/jats:italic>\u2009=\u20090.008), chlorambucil (<jats:italic>P<\/jats:italic>\u2009=\u20090.003), and anticoagulant (<jats:italic>P<\/jats:italic>\u2009=\u20090.02). VDI was also significantly correlated with age (<jats:italic>P<\/jats:italic>\u2009=\u20090.033), disease duration (<jats:italic>P<\/jats:italic>\u2009=\u20090.029), and duration of eye involvement (<jats:italic>P<\/jats:italic>\u2009=\u20090.003).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>VDI is significantly associated with most disease parameters of BD, except for parameters such as mucocutaneous manifestations and uncomplicated venous thrombosis; however, further studies may be needed to establish BD-specific damage index.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-021-00193-5","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T14:47:49Z","timestamp":1623250069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Vasculitis damage index in Beh\u00e7et\u2019s disease"],"prefix":"10.1186","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5930-2885","authenticated-orcid":false,"given":"Fatema T.","family":"Elgengehy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif M.","family":"Gamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesreen","family":"Sobhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahem","family":"Siam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada W.","family":"Elhady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer A.","family":"Gheita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"issue":"6","key":"193_CR1","first-page":"100","volume":"35 Suppl 108","author":"AD Protogerou","year":"2017","unstructured":"Protogerou AD, Nasothimiou EG, Sfikakis PP, Tzioufas AG. Non-invasive vascular biomarkers in patients with Beh\u00e7et's disease: review of the data and future perspectives. Clin Exp Rheumatol. 2017;35 Suppl 108(6):100\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"193_CR2","first-page":"636","volume":"28","author":"M Schirmer","year":"2001","unstructured":"Schirmer M, Calamia KT, Direskeneli H. Ninth international conference on Beh\u00e7et\u2019s disease, Seoul, Korea, May 27-29, 2000. J Rheumatol. 2001;28(3):636\u20139.","journal-title":"J Rheumatol"},{"key":"193_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"F Davatchi","year":"2014","unstructured":"Davatchi F, Assaad-Khalil S, Calamia K, Crook JE, Sadeghi-Abdollahi B, Schirmer M, et al. The international criteria for Beh\u00e7et\u2019s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338\u201347.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"193_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s11739-018-1991-y","volume":"14","author":"G Emmi","year":"2019","unstructured":"Emmi G, Bettiol A, Silvestri E, Di Scala G, Becatti M, Fiorillo C, et al. Vascular Beh\u00e7et's syndrome: an update. Intern Emerg Med. 2019;14(5):645\u201352. https:\/\/doi.org\/10.1007\/s11739-018-1991-y.","journal-title":"Intern Emerg Med"},{"issue":"2","key":"193_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.revmed.2013.12.002","volume":"35","author":"AC Desbois","year":"2014","unstructured":"Desbois AC, Wechsler B, Cluzel P, Helft G, Boutin D, Piette JC, et al. Cardiovascular involvement in Beh\u00e7et's disease. Rev Med Interne. 2014;35(2):103\u201311. https:\/\/doi.org\/10.1016\/j.revmed.2013.12.002.","journal-title":"Rev Med Interne"},{"key":"193_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/1756-185X.13298","volume":"22","author":"F Alibaz-Oner","year":"2019","unstructured":"Alibaz-Oner F, Direskeneli H. Management of vascular Behcet\u2019s disease. Int J Rheum Dis. 2019;22:105\u20138. https:\/\/doi.org\/10.1111\/1756-185X.13298.","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"193_CR7","first-page":"583","volume":"87","author":"S Ketari Jamoussi","year":"2009","unstructured":"Ketari Jamoussi S, Chaaba H, Ben Dhaou B, Boussema F, Kochbati S, Cherif O, et al. Arterial involvement in Behcet's disease: a series of 7 cases. Tunis Med. 2009;87(9):583\u20138.","journal-title":"Tunis Med"},{"issue":"1","key":"193_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/BOR.0b013e3282f370d1","volume":"20","author":"D Jayne","year":"2008","unstructured":"Jayne D. Challenges in the management of microscopic polyangiitis: past, present and future. Curr Opin Rheumatol. 2008;20(1):3\u20139. https:\/\/doi.org\/10.1097\/BOR.0b013e3282f370d1.","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"193_CR9","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/ard.2007.071936","volume":"67","author":"C Mukhtyar","year":"2008","unstructured":"Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, et al. Outcomes from studies of anti-neutrophil cytoplasm antibody associated vasculitis: a systematic review by the European league against rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008;67(7):1004\u201310. https:\/\/doi.org\/10.1136\/ard.2007.071936.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"193_CR10","first-page":"1357","volume":"34","author":"P Seo","year":"2007","unstructured":"Seo P, Luqmani RA, Flossmann O, Hellmich B, Herlyn K, Hoffman GS, et al. The future of damage assessment in vasculitis. J Rheumatol. 2007;34(6):1357\u201371.","journal-title":"J Rheumatol"},{"issue":"2","key":"193_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/art.1780400222","volume":"40","author":"AR Exley","year":"1997","unstructured":"Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40(2):371\u201380. https:\/\/doi.org\/10.1002\/art.1780400222.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"193_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.berh.2008.12.004","volume":"23","author":"RA Watts","year":"2009","unstructured":"Watts RA, Scott DG. Recent developments in the classification and assessment of vasculitis. Best Pract Res Clin Rheumatol. 2009;23(3):429\u201343. https:\/\/doi.org\/10.1016\/j.berh.2008.12.004.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"193_CR13","unstructured":"Piga M. Beh\u00e7et's Disease Overall Damage Index (BODI). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03803462"},{"key":"193_CR14","doi-asserted-by":"publisher","first-page":"e001192","DOI":"10.1136\/rmdopen-2020-001192","volume":"6","author":"M Piga","year":"2020","unstructured":"Piga M, Floris A, Espinosa G, et al. Development and preliminary validation of the Beh\u00e7et's syndrome overall damage index (BODI). RMD Open. 2020;6:e001192. https:\/\/doi.org\/10.1136\/rmdopen-2020-001192.","journal-title":"RMD Open"},{"key":"193_CR15","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 2018;77:808\u201318. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213225.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"193_CR16","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis. 2008;67(12):1656\u201362. https:\/\/doi.org\/10.1136\/ard.2007.080432 Epub 2008 Jan 31.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"193_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/rheumatology\/keg453","volume":"43","author":"G Lawton","year":"2004","unstructured":"Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Beh\u00e7et\u2019s disease activity index. Rheumatology. 2004;43(1):73\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keg453.","journal-title":"Rheumatology."},{"issue":"3","key":"193_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10067-018-4344-3","volume":"38","author":"HS Zayed","year":"2019","unstructured":"Zayed HS, Medhat BM, Seif EM. Evaluation of treatment adherence in patients with Beh\u00e7et's disease: its relation to disease manifestations, patients' beliefs about medications, and quality of life. Clin Rheumatol. 2019;38(3):761\u20138. https:\/\/doi.org\/10.1007\/s10067-018-4344-3.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"193_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82(1):60\u201376. https:\/\/doi.org\/10.1097\/00005792-200301000-00006.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"193_CR20","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s11926-008-0071-0","volume":"10","author":"LH Silveira","year":"2008","unstructured":"Silveira LH. Damage assessment in systemic vasculitis. Curr Rheumatol Rep. 2008;10(6):436\u201341. https:\/\/doi.org\/10.1007\/s11926-008-0071-0.","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"193_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4081\/reumatismo.2019.1223","volume":"71","author":"DHS Attia","year":"2019","unstructured":"Attia DHS, Abdel Noor RA. Severe Beh\u00e7et\u2019s disease equally affects both genders in Egyptian patients: a multicentre retrospective follow-up study. Reumatismo. 2019;71(4):218\u201325.","journal-title":"Reumatismo."},{"key":"193_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejr.2018.05.006","volume":"14","author":"A El-Garf","year":"2019","unstructured":"El-Garf A, Abdo M, Alkemary A, Mohamed S. Beh\u00e7et\u2019s disease patterns and subsets in a cohort of Egyptian patients. Egypt Rheumatol. 2019;14:135\u20138. https:\/\/doi.org\/10.1016\/j.ejr.2018.05.006.","journal-title":"Egypt Rheumatol"},{"issue":"4","key":"193_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.5152\/eurjrheum.2016.038","volume":"3","author":"DU Cansu","year":"2016","unstructured":"Cansu DU, Ka\u015fifo\u011flu T, Korkmaz C. Do clinical findings of Beh\u00e7et\u2019s disease vary by gender?: a single-center experience from 329 patients. Eur J Rheumatol. 2016;3(4):157\u201360. https:\/\/doi.org\/10.5152\/eurjrheum.2016.038.","journal-title":"Eur J Rheumatol"},{"issue":"28","key":"193_CR24","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1097\/MD.0000000000000263","volume":"93","author":"X Wu","year":"2014","unstructured":"Wu X, Li G, Huang X, et al. Behcet\u2019s disease complicated with thrombosis. A report of 93 Chinese cases. Medicine. 2014;93(28):e263. https:\/\/doi.org\/10.1097\/MD.0000000000000263.","journal-title":"Medicine"},{"issue":"6","key":"193_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.autrev.2017.12.006","volume":"17","author":"A Greco","year":"2018","unstructured":"Greco A, De Virgilio A, Ralli M, Ciofalo A, Mancini P, Attanasio G, et al. Beh\u00e7et's disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018;17(6):567\u201375. https:\/\/doi.org\/10.1016\/j.autrev.2017.12.006.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"193_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1177\/0961203315576858","volume":"24","author":"MC Amigo","year":"2015","unstructured":"Amigo MC, Goycochea-Robles MV, Espinosa-Cuervo G, Medina G, Barrag\u00e1n-Garfias JA, Vargas A, et al. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus. 2015;24(9):927\u201334. https:\/\/doi.org\/10.1177\/0961203315576858.","journal-title":"Lupus"},{"issue":"1","key":"193_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/MD.0b013e3182428126","volume":"91","author":"D Saadoun","year":"2012","unstructured":"Saadoun D, Asli B, Wechsler B, Houman H, Geri G, Desseaux K, et al. Long-term outcome of arterial lesions in Beh\u00e7et disease: a series of 101 patients. Medicine. 2012;91(1):18\u201324. https:\/\/doi.org\/10.1097\/MD.0b013e3182428126.","journal-title":"Medicine."},{"issue":"1","key":"193_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/09273948.2017.1384026","volume":"27","author":"P Yang","year":"2019","unstructured":"Yang P, Huang G, Du L, Ye Z, Hu K, Wang C, et al. Long-term efficacy and safety of interferon alpha-2a in the treatment of Chinese patients with Beh\u00e7et's uveitis not responding to conventional therapy. Ocul Immunol Inflamm. 2019;27(1):7\u201314. https:\/\/doi.org\/10.1080\/09273948.2017.1384026.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"193_CR29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/art.1780390303","volume":"39","author":"D Gladman","year":"1996","unstructured":"Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the systemic lupus international collaborating clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363\u20139. https:\/\/doi.org\/10.1002\/art.1780390303.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"193_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12886-018-0929-5","volume":"18","author":"H Celiker","year":"2018","unstructured":"Celiker H, Kazokoglu H, Direskeneli H. Conventional immunosuppressive therapy in severe Behcet's uveitis: the switch rate to the biological agents. BMC Ophthalmol. 2018;18(1):261. https:\/\/doi.org\/10.1186\/s12886-018-0929-5.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"193_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1590\/S0004-27492010000100007","volume":"73","author":"JM Zaghetto","year":"2010","unstructured":"Zaghetto JM, Yamamoto MM, Souza MB, Silva FT, Hirata CE, Olivalves E, et al. Chlorambucil and cyclosporine a in Brazilian patients with Beh\u00e7et's disease uveitis: a retrospective study. Arq Bras Oftalmol. 2010;73(1):40\u20136. https:\/\/doi.org\/10.1590\/S0004-27492010000100007.","journal-title":"Arq Bras Oftalmol"},{"issue":"5","key":"193_CR32","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/00045391-200209000-00015","volume":"9","author":"B Goker","year":"2002","unstructured":"Goker B, Goker H. Current therapy for Beh\u00e7et's disease. Am J Ther. 2002;9(5):465\u201370. https:\/\/doi.org\/10.1097\/00045391-200209000-00015.","journal-title":"Am J Ther"},{"issue":"5","key":"193_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1053\/sarh.2001.19819","volume":"30","author":"VG Kaklamani","year":"2001","unstructured":"Kaklamani VG, Kaklamanis PG. Treatment of Beh\u00e7et's disease--an update. Semin Arthritis Rheum. 2001;30(5):299\u2013312. https:\/\/doi.org\/10.1053\/sarh.2001.19819.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"193_CR34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/rheumatology\/kew457","volume":"56","author":"CY Hsu","year":"2017","unstructured":"Hsu CY, Lin MS, Su YJ, Cheng TT, Lin YS, Chen YC, et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology (Oxford). 2017;56(4):620\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kew457.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"193_CR35","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3109\/08830185.2013.863305","volume":"33","author":"T Caza","year":"2014","unstructured":"Caza T, Oaks Z, Perl A. Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus. Int Rev Immunol. 2014;33(4):330\u201363. https:\/\/doi.org\/10.3109\/08830185.2013.863305.","journal-title":"Int Rev Immunol"},{"issue":"9","key":"193_CR36","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1002\/art.27568","volume":"62","author":"D Saadoun","year":"2010","unstructured":"Saadoun D, Wechsler B, Desseaux K, Le Thi HD, Amoura Z, Resche-Rigon M, et al. Mortality in Beh\u00e7et's disease. Arthritis Rheum. 2010;62(9):2806\u201312. https:\/\/doi.org\/10.1002\/art.27568.","journal-title":"Arthritis Rheum"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-021-00193-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-021-00193-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-021-00193-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T15:02:08Z","timestamp":1623250928000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-021-00193-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["193"],"URL":"https:\/\/doi.org\/10.1186\/s42358-021-00193-5","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"6 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and approved by the local ethical committee. Informed consent was obtained from the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors gave their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}